Globus Medical, Inc. (GMED) – What Are Brokerages Saying About This Stock?

Shares of Globus Medical, Inc. (NYSE:GMED) have been given a consensus recommendation of “Moderate Buy” by the seventeen brokerages that are presently covering the firm, MarketBeat Ratings reports. Five investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and three have issued a strong buy rating on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $99.46.

A number of analysts have recently weighed in on GMED shares. Weiss Ratings restated a “hold (c+)” rating on shares of Globus Medical in a research note on Friday, October 9th. BMO Capital Markets started coverage on Globus Medical in a report on Wednesday, July 8th. They issued an “outperform” rating and a $94.00 price target for the company. Royal Bank Of Canada reduced their price target on shares of Globus Medical from $115.00 to $85.00 and set an “outperform” rating on the stock in a research report on Thursday, October 1st. Zacks Research raised shares of Globus Medical from a “hold” rating to a “strong-buy” rating in a report on Monday, August 10th. Finally, Stifel Nicolaus lowered their price objective on shares of Globus Medical from $95.00 to $80.00 and set a “hold” rating for the company in a research report on Wednesday, July 8th.

Globus Medical Trading Down 5.9%

NYSE GMED opened at $77.98 on Friday. Globus Medical has a 1-year low of $59.51 and a 1-year high of $101.40. The company has a 50 day moving average of $77.64 and a 200-day moving average of $83.51. The firm has a market cap of $10.47 billion, a price-to-earnings ratio of 16.85, a PEG ratio of 1.33 and a beta of 0.96.

Globus Medical (NYSE:GMED) last announced its earnings results on Thursday, August 6th. The medical device company reported $1.34 EPS for the quarter, topping the consensus estimate of $1.10 by $0.24. Globus Medical had a return on equity of 14.57% and a net margin of 17.02%. The business had revenue of $789.61 million for the quarter, compared to the consensus estimate of $782.88 million. During the same period in the previous year, the business earned $0.86 EPS. Globus Medical’s revenue was up 5.9% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. On average, analysts forecast that Globus Medical will post 4.99 earnings per share for the current year.

Trending Headlines about Globus Medical

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Zacks Research raised EPS estimates across multiple periods, including Q3 2026 to $1.19, FY2026 to $4.98, FY2027 to $5.07, and FY2028 to $5.89. The firm also lifted estimates for Q1 2027, Q2 2027 and Q2 2028 by $0.01 each and maintained a “Strong-Buy” rating. The revisions suggest modestly improving expectations for Globus Medical’s earnings outlook. MarketBeat Globus Medical analyst estimates
• Positive Sentiment: Globus Medical was highlighted as a healthcare technology stock positioned for digital-health growth. Zacks cited projected 2026 earnings growth, an attractive valuation and innovation in essential medical services as reasons the company could benefit from broader healthcare technology adoption. Zacks healthcare technology stocks article
• Positive Sentiment: Another analysis called GMED undervalued even after a 77% run. This supports the view that analysts see additional upside based on Globus Medical’s earnings prospects and valuation, although the large prior gain may also encourage profit-taking. Globus Medical stock looks undervalued article
• Neutral Sentiment: The estimate increases were small—generally just $0.01 per share—and Zacks’ FY2026 estimate of $4.98 remains slightly below the broader consensus of $4.99. As a result, the revisions provide incremental support but may not be strong enough to overcome near-term selling pressure.
• Negative Sentiment: With GMED having already advanced substantially, investors may be locking in gains while waiting for a larger earnings or guidance catalyst. This profit-taking dynamic appears to be outweighing the otherwise favorable analyst commentary today.

Insiders Place Their Bets

In other Globus Medical news, Director Stephen Zarrilli sold 25,000 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $87.04, for a total value of $2,176,000.00. Following the transaction, the director directly owned 25,000 shares in the company, valued at approximately $2,176,000. This trade represents a 50.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director James R. Tobin sold 30,000 shares of Globus Medical stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $74.58, for a total value of $2,237,400.00. Following the completion of the sale, the director directly owned 15,000 shares of the company’s stock, valued at $1,118,700. This trade represents a 66.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 18.38% of the stock is currently owned by company insiders.

Institutional Trading of Globus Medical

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Janus Henderson Group PLC boosted its position in Globus Medical by 4.5% during the first quarter. Janus Henderson Group PLC now owns 7,623,095 shares of the medical device company’s stock worth $656,831,000 after purchasing an additional 328,217 shares during the period. Sculptor Capital LP increased its holdings in shares of Globus Medical by 1.9% in the first quarter. Sculptor Capital LP now owns 3,058,000 shares of the medical device company’s stock valued at $263,477,000 after purchasing an additional 58,000 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Globus Medical by 2.0% in the first quarter. Dimensional Fund Advisors LP now owns 1,769,897 shares of the medical device company’s stock valued at $152,474,000 after purchasing an additional 33,976 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in shares of Globus Medical by 2.8% in the first quarter. The Manufacturers Life Insurance Company now owns 1,132,278 shares of the medical device company’s stock valued at $97,557,000 after purchasing an additional 30,412 shares during the period. Finally, Arrowstreet Capital Limited Partnership raised its position in shares of Globus Medical by 107.0% in the first quarter. Arrowstreet Capital Limited Partnership now owns 912,905 shares of the medical device company’s stock valued at $78,656,000 after purchasing an additional 471,875 shares during the period. 95.16% of the stock is currently owned by institutional investors and hedge funds.

About Globus Medical

Globus Medical, Inc develops and commercializes musculoskeletal solutions for surgeons, hospitals and patients. The company focuses primarily on spinal, orthopedic trauma and other orthopedic procedures, offering implants, instruments and related technologies designed to support surgical treatment and improve clinical outcomes.

Its product portfolio includes spinal implants and enabling technologies, including the ExcelsiusGPS robotic navigation platform and Excelsius3D imaging system.